CLINICAL_TRIALS
trial_result
· 2015-09-09
Clinical Trial Update: The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin [Phase 3]
Summary
Phase 3 trial evaluating tafamidis in patients with transthyretin familial amyloid polyneuropathy completed, with results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Transthyretin Familial Amyloid Polyneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2015-09-09